STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: LinkMed’s (STO:LMED) portfolio company Ortoviva’s development work is progressing well and testing carried out by the company has yielded very positive results. The company plans to start clinical testing in early 2008. ”Thanks to careful and focused work in close consultation with surgeons and disc implantation companies, we have achieved very positive results in a short timeframe. We will be carrying out some additional development work in order to start clinical testing at the beginning of 2008,” says Ortoviva’s CEO, Stan Mikulowski, who is also Senior Venture Manager at LinkMed.
